Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia

Jayna J Mistry, Charlotte Hellmich, Amelia Lambert, Jamie A Moore, Aisha Jibril, Angela Collins, Kristian M Bowles, Stuart A Rushworth

Research output: Contribution to journalLetter

6 Downloads (Pure)

Abstract

Acute myeloid leukemia (AML) remains an incurable malignancy despite recent advances in treatment. Recently a number of new therapies have emerged for the treatment of AML which target BCL-2 or the membrane receptor CD38. Here, we show that treatment with Venetoclax and Daratumumab combination resulted in a slower tumor progression and a reduced leukemia growth both in vitro and in vivo. These data provide evidence for clinical evaluation of Venetoclax and Daratumumab combination in the treatment of AML.

Original languageEnglish
Article number35
JournalBiomarker Research
Volume9
Issue number1
DOIs
Publication statusPublished - 13 May 2021

Cite this